Better Buy: Biogen vs. Axsome Therapeutics

If you've seen one biotech, you've seen... one biotech. They're all different, with unique opportunities and challenges. And beyond their core differences, their situations vary widely depending on what stage of their business lives they are in.

Biogen (NASDAQ: BIIB), for example, is well established. It has made billions of dollars through the years from its multiple sclerosis (MS) franchise and has now expanded into new therapeutic categories. Axsome Therapeutics (NASDAQ: AXSM), on the other hand, is young enough that it doesn't have any approved products on the market yet, but its pipeline includes several highly promising candidates.

Which of these two biotech stocks is the better pick for long-term investors? Here's how big Biogen stacks up against up-and-coming Axsome.

Source Fool.com